LinkSêq genotyping: Fast, easy molecular antigen typing

Matthew Frome
Thermo Fisher Scientific, USA

Statement of the Problem: Blood typing using serology can provide an inaccurate answer if a patient is recently transfused, taking oncology therapeutics like Darzalex, or has weak or partial antigens. Antisera are not always available for rare antigens. Chronically transfused patients can avoid alloimmunization by receiving antigen-negative blood units, but building a complete patient or donor antigen profile using serology is labor-intensive and can take days. Blood genotyping using traditional methods such as SSP and SSO overcome the limitations of serotyping, but require long, labor-intensive workflows and limited resolution. Blood genotyping using Sanger or NGS sequencing technology have high resolution, but are even more time and labor consuming, expensive and require interpretation by subject matter experts.

Solution: Thermo Fisher Scientific’s Link Sêq real-time PCR technology accelerates turn-around times reducing laboratory costs and provides medium to high resolution results that can be interpreted by clinicians and interrogated by genotyping experts. LinkSêq utilizes allele specific PCR reactions to identify important variants and its SureTyper™ software analyzes reaction results to automatically determine the genotype and predict a phenotype. LinkSêq was developed over 10 years ago for genotyping the complex Human Leukocyte Antigen (HLA) system and can be performed on the same equipment as real-time PCR based HLA typing assays, which are widely used for deceased donor typing.

Conclusion & Significance: LinkSêq blood genotyping solutions overcome the major challenges of molecular typing by providing a robust, automated approach that increases laboratory productivity and reduces turn-around time. With less than 10 minutes of hands on set-up, no further operator intervention with reagents and SureTyper software by fully automating all analysis, LinkSêq delivers genotyping and predicted phenotyping results in approximately 90 minutes.

Recent Publications


Biography

Matthew Frome is Senior Manager of Business Development at Thermo Fisher Scientific. He brings over 20 years of industry experience. Most recently, he was VP of Business Development at Linkage Biosciences (acquired by Thermo Fisher Scientific in 2018), and Director of Business Development at Solazyme. Before Solazyme, author founded Focus Biology, a start-up bioinformatics company. Prior to Focus, he held various roles of increasing responsibility at GE Healthcare (Amersham Biosciences/Molecular Dynamics), Sangamo Biosciences, Applied Biosystems and Sungene Technologies. He received an MBA and Masters of Public Health from the University of California, Berkeley and a MS in Biology from Stanford University.

matthew.frome@thermofisher.com